Skip to Main Content

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Conditions

Immune System

Phase III

What is the purpose of this trial?

To evaluate the long-term safety and tolerability of seladelpar.

  • Ages
    18 years - 75 years
  • Gender
    Both
Find out more about who can participate in this trial
  • Trial with
    CymaBay Therapeutics, Inc.
  • Start Date
    07/27/2021
  • End Date
    12/31/2024

For more information about this study, contact:

Suzie Christopher

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Sub-Investigator

  • Last Updated
    11/09/2021
  • Study HIC
    #2000030598

Contact Information

For more information about this study, including how to volunteer, contact Suzie Christopher

Volunteer Now